Safety profile of clobazam in the real world: an analysis of FAERS database and systematic review of case reports

References

• Ng YT, Collins SD, Clobazam. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. 2007 Jan; 4(1):138–144. PubMed PMID: 17199029; PubMed Central PMCID: PMCPMC7479695. eng. DOI:10.1016/j.nurt.2006.11.002
   Google Scholar
• LABEL: CLOBAZAM- clobazam tablet 2022 [updated 2021-Sep-25]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=721dde68-db83-4dad-8649-8046cb455372#section-12
   Google Scholar
• Product monograph including patient medication information: fRISIUM®clobazam 2022 [updated 2015-6-15]. Available from: https://pdf.hres.ca/dpd_pm/00030962.PDF
   Google Scholar
• Pernea M, Sutcliffe AG. Clobazam and its use in epilepsy. Pediatr Rep. 2016 Jun 15;8(2):6516. PubMed PMID: 27433306; PubMed Central PMCID: PMCPMC4933812. eng. DOI:10.4081/pr.2016.6516
   PubMedGoogle Scholar
• Böhm R, Bulin C, Waetzig V, et al. Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Br J Clin Pharmacol. 2021 Nov;87(11):4421–4431. PubMed PMID: 33871897; eng. DOI:10.1111/bcp.14868.
   PubMed Web of Science ®Google Scholar
• Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001 Oct;10(6):483–486. PubMed PMID: 11828828; eng. DOI:10.1002/pds.677.
   PubMed Web of Science ®Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002 Jan;11(1):3–10. PubMed PMID: 11998548; eng. DOI:10.1002/pds.668.
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharm Therap. 1981 Aug;30(2):239–245. PubMed PMID: 7249508; eng. DOI:10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Petursson H, Lader MH. Withdrawal reaction from clobazam. Br Med J (Clinical Research Ed). 1981 Jun 13;282(6280):1931–1932. PubMed PMID: 6113026; PubMed Central PMCID: PMCPMC1505805. eng. DOI:10.1136/bmj.282.6280.1931.
   PubMedGoogle Scholar
• Machet L, Vaillant L, Dardaine V, et al. Patch testing with clobazam: relapse of generalized drug eruption. Contact Dermatitis. 1992 May;26(5):347–348. PubMed PMID: 1395600; eng. DOI:10.1111/j.1600-0536.1992.tb00132.x
   PubMed Web of Science ®Google Scholar
• Caramaschi P, Biasi D, Carletto A, et al. Clobazam-induced systemic lupus erythematosus. Clin Rheumatol. 1995 Jan;14(1):116. PubMed PMID: 7743738; eng. DOI:10.1007/bf02208098
   PubMed Web of Science ®Google Scholar
• Redondo P, Vicente J, España A, et al. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol. 1996 Dec;135(6):999–1002. PubMed PMID: 8977728; eng. DOI:10.1046/j.1365-2133.1996.d01-1111.x
   PubMed Web of Science ®Google Scholar
• Setterfield JF, Robinson R, MacDonald D, et al. Coma-induced bullae and sweat gland necrosis following clobazam [Article]. Clin Exp Dermatol. 2000;25(3):215–218. English. DOI:10.1046/j.1365-2230.2000.00619.x
   PubMed Web of Science ®Google Scholar
• Contin M, Sangiorgi S, Riva R, et al. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit. 2002 Dec;24(6):737–741. PubMed PMID: 12451290; eng. DOI:10.1097/00007691-200212000-00009
   PubMed Web of Science ®Google Scholar
• Tanaka J, Yoshida I, Mimaki T. A case with oliguria and edema during the treatment with clobazam. J Japan Epilepsy Soc. 2002;20(3):180–184. Article Japanese. DOI:10.3805/jjes.20.180.
   Google Scholar
• Iwasaki T, Miura H, Sunaoshi W, et al. [A case of intractable epilepsy showing frequent gelastic seizures by administration of clobazam]. No to Hattatsu = Brain and Dev. 2003 Sep;35(5):406–410. PubMed PMID: 13677950; jpn.
   PubMedGoogle Scholar
• Aylett SE, Cross H, Berry D. Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. Dev Med Child Neurol. 2006 Jul;48(7):612–615. PubMed PMID: 16780634; eng. DOI:10.1017/s0012162206001289.
   PubMed Web of Science ®Google Scholar
• Wakamoto H, Kume A, Nakano N, et al. Benign angiopathy of the central nervous system associated with phenytoin intoxication. Brain & Development. 2006 Jun;28(5):336–338. PubMed PMID: 16376047; eng. DOI:10.1016/j.braindev.2005.10.003
   PubMed Web of Science ®Google Scholar
• Ertam I, Sezgin AO, Unal I. A case with Stevens Johnson syndrome triggered by combination of clobazam, lamotrigine, and valproic acid treatment. Int J Dermatol. 2009 Jan;48(1):98–99. PubMed PMID: 19126064; eng. DOI:10.1111/j.1365-4632.2009.03865.x.
   PubMed Web of Science ®Google Scholar
• Pok PR, Mauras M, De Saint Léger MN, et al. Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate. Leg Med (Tokyo). 2010 Nov;12(6):300–304. PubMed PMID: 20870445; eng. DOI:10.1016/j.legalmed.2010.08.002.
   PubMed Web of Science ®Google Scholar
• Barvaliya M, Sanmukhani J, Patel TK, et al. Phenytoin induced chorea in a pediatric patient: an interaction between phenytoin, phenobarbital and clobazam [Conference Paper]. Indian J Pharmacol. 2011;43(6):731–732. English. DOI:10.4103/0253-7613.89839
   PubMed Web of Science ®Google Scholar
• Naccarato M, Yoong D, Kovacs C, et al. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17(3):589–592. PubMed PMID: 22293514; eng. DOI:10.3851/imp1953
   PubMed Web of Science ®Google Scholar
• Balamtekin N, Kilić S, Arslan M, et al. Stevens Johnson syndrome triggered by combination of clobazam, lamotrigine and valproic acid in a child [Conference Abstract]. Allergy: European Journal of Allergy and Clinical Immunology. 2013;68:p. 282. DOI:10.1111/all.12250. English.
   Google Scholar
• Dang CD, Beets-Shay L, Kahn EC. Toxic epidermal necrolysis triggered by clobazam: a case report in a 13-year-old girl. Pediatr Dermatol. 2015 May;32(3):e102–3. PubMed PMID: 25690725; eng. DOI:10.1111/pde.12527.
   PubMed Web of Science ®Google Scholar
• Gauthier AC, Quraishi IH, Mattson RH. Hypothermia associated with clobazam use in adult epilepsy. Epilepsy & behavior case reports. 2016;5:17–18. PubMed PMID: 26870662; PubMed Central PMCID: PMCPMC4739151. eng. DOI:10.1016/j.ebcr.2016.01.002.
   Google Scholar
• Incecik F, Ozcanyüz DG. Unusual side effects due to clobazam: a case report with edema of the extremities. Acta Neurol Belg. 2018 Sep;118(3):521–522. PubMed PMID: 29524094; eng. DOI:10.1007/s13760-018-0901-4.
   PubMed Web of Science ®Google Scholar
• Morimoto M, Shimakawa S, Hashimoto T, et al. Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome. J Clin Pharm Therapeutics. 2018 Aug;43(4):571–573. PubMed PMID: 29265387; eng. DOI:10.1111/jcpt.12659
   PubMed Web of Science ®Google Scholar
• Thomas RJ, Chawla J Central hypoventilation in a paediatric patient with angelman syndrome [Conference Abstract]. Journal of Sleep Research. 2018;27. doi: 10.1111/jsr.12766. English.
   Google Scholar
• Parman MG, Holmes AP. Hypothermia in an adolescent due to probable drug-drug interaction involving clobazam. J Pediatr Pharmacol Ther. 2019 Mar;24(2):156–159. PubMed PMID: 31019409; PubMed Central PMCID: PMCPMC6478366. eng. DOI:10.5863/1551-6776-24.2.156.
   PubMedGoogle Scholar
• Razanapinaritra R, El Fetoiki FZ, Hali F, et al. DRESS syndrome induced by clobazam in a child: a new case [Article]. Revue Francaise d’Allergologie. 2019;59(4):346–349. English French. DOI:10.1016/j.reval.2019.01.004.
   Web of Science ®Google Scholar
• Aung T, Shvarts V. Rare but life-threatening aspiration pneumonia related to initiation of clobazam therapy. Epilepsy & Behavior Reports. 2020;14:100406. PubMed PMID: 33313501; PubMed Central PMCID: PMCPMC7720012. eng. DOI:10.1016/j.ebr.2020.100406.
   PubMedGoogle Scholar
• Hamilton KE, Shelton CM, Wheless J, et al. Persistent hypersomnolence following clobazam in a child with epilepsy and undiagnosed CYP2C19 polymorphism. J Pediatr Pharmacol Ther. 2020;25(4):320–327. PubMed PMID: 32461746; PubMed Central PMCID: PMCPMC7243903. eng. DOI:10.5863/1551-6776-25.4.320
   PubMedGoogle Scholar
• Hussain K, Zaheri S, Patel N. Drug reaction with eosinophilia and systemic symptoms complicated by haemophagocytic lymphohistiocytosis: is screening required? English [Conference Abstract]. British J Dermatol. 2020;183(SUPPL 1):20. DOI:10.1111/bjd.18967
   Google Scholar
• Manyas H, Paketci C, Okur D, et al. A drug reaction with eosinophilia and systemic symptoms syndrome associated with clobazam. Pediatr Emerg Care. 2020 Mar;36(3):e175. PubMed PMID: 30870346; eng. DOI:10.1097/pec.0000000000001754
   PubMed Web of Science ®Google Scholar
• Bates BK, Fletcher JL, Hintze T, et al. Acute encephalopathy in the setting of toxic clobazam (ONFI) metabolite levels and the unassuming antidote [Conference Abstract]. Journal of Medical Toxicology. 2021;17:p. 113. DOI:10.1007/s13181-021-00832-9. English.
   Google Scholar
• Ulusoy I, Ocak R, Erdem M, et al. Meropenem induced respiratory arrest [Conference Abstract]. Pediatr Crit Care Med. 2021;22(SUPPL 1):71–72. English. DOI:10.1097/01.pcc.0000738652.83592.9c.
   Google Scholar
• Conry JA, Y-T N, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009;50(5):1158–1166. DOI:10.1111/j.1528-1167.2008.01935.x
   PubMed Web of Science ®Google Scholar
• Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77(15):1473–1481. DOI:10.1212/WNL.0b013e318232de76
   PubMed Web of Science ®Google Scholar
• Ng YT, Conry J, Paolicchi J, et al. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy & Behavior: E&B. 2012 Dec;25(4):687–694. PubMed PMID: 23141144; eng. DOI:10.1016/j.yebeh.2012.09.039.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kumar A. Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis. Acta Neurol Scand. 2022 Aug 27;146(5):623–627. PubMed PMID: 36029138; eng. DOI:10.1111/ane.13690
   PubMed Web of Science ®Google Scholar
• Volz M, Christ O, Kellner HM, et al. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol. 1979;7(Suppl 1):41s–50s. PubMed PMID: 35204; PubMed Central PMCID: PMCPMC1429544. eng. DOI:10.1111/j.1365-2125.1979.tb04664.x.
   PubMedGoogle Scholar
• Giraud C, Tran A, Rey E, et al. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug metabolism and disposition: the biological fate of chemicals. 2004 Nov;32(11):1279–1286. PubMed PMID: 15483195; eng. DOI:10.1124/dmd.32.11.1279.
   Google Scholar
• Harrison MP, Haworth SJ, Moss SR, et al. The disposition and metabolic fate of 14C-meropenem in man. Xenobiotica; the fate of foreign compounds in biological systems. 1993 Nov;23(11):1311–1323. PubMed PMID: 8310714; eng. DOI:10.3109/00498259309059441
   Google Scholar
• Mahmoudi M, Brenner T, Hatiboglu G, et al. Substantial impairment of voriconazole clearance by high-dose meropenem in a patient with renal failure. Clin Infect Dis. 2017 Sep 15;65(6):1033–1036. PubMed PMID: 28505263; eng. DOI:10.1093/cid/cix443
   PubMed Web of Science ®Google Scholar